Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 148
Views PDF: 116
DOI: https://doi.org/10.51298/vmj.v526i1B.5421
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Phùng , T. H. ., & Lê, T. Y. . (2023). EVALUATION OF FACTORS ASSOCIATED WITH TREATMENT OUTCOME OF ADJUVANT DOCETAXEL-CARBOPLATIN-TRASTUZUMAB REGIMEN IN HER2/NEU POSITIVE BREAST CANCER. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5421

EVALUATION OF FACTORS ASSOCIATED WITH TREATMENT OUTCOME OF ADJUVANT DOCETAXEL-CARBOPLATIN-TRASTUZUMAB REGIMEN IN HER2/NEU POSITIVE BREAST CANCER

Thị Huyền Phùng 1,, Thị Yến Lê1
1 k hospital

Main Article Content

Abstract

Aims: Analyze factors associated with treatment outcome of adjuvant docetaxel-carboplatin-trastuzumab in stage I-IIIA HER2 positive breast cancer. Patients and methods: Retrospective-prospective descriptive study on 51 patients with stage I-IIIA breast cancer who underwent mastectomy or breast conserving surgery with axillary dissection and treated with adjuvant docetaxel – carboplatin – trastuzumab, with or without radiotherapy and endocrine therapy at K hospital from 01/2014 to 05/2021, with follow up until 05/2022. Results: Docetaxel-carboplatin-trastuzumab regimen improved disease free survival (DFS), with the rate of 1 year, 2 year, 3 year, 4 year and 5 year DFS of 100%, 100%, 100%, 92% and 83.7% respectively; lymph node metastasis was associated with DFS. Conclusions: Patients with stage I-IIIA HER2n positive breast cancer should be treated with adjuvant chemotherapy and anti-HER2 therapy after surgery.

Article Details

Keywords

breast cancer, HER2/neu, docetaxel, carboplatin, trastuzumab.

References

1. GLOBOCAN 2020: New Global Cancer Data | UICC. Accessed June 13, 2021. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
2. Điều Trị Nội Khoa Bệnh Ung Thư Vú. Nhà xuất bản Y học, Hà Nội; 2011.
3. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistoch emistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69. doi:10.3816/cbc.2004.n.011
4. Slamon D, Eiermann W, Robert N, et al. Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Research. 2016;76:S5-04. doi:10.1158/1538-7445.SABCS15-S5-04
5. BCIRG 006. TRIOTM. Accessed August 1, 2021. https:// www.trioncol ogy.org/studies/bcirg-006/
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine. 2005;353(16):1673-1684. doi:10.1056/NEJ Moa052122
7. Nowikiewicz T, Wiśniewska M, Wiśniewski M, et al. Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz – analysis of more than six years of follow-up. Contemp Oncol (Pozn). 2015;19(4):284-289. doi:10.5114/ wo.2015.54387.
8. Nguyễn Thái Sơn. Đánh giá kết quả hóa trị bổ trợ kết hợp Trastuzumab trên bệnh nhân ung thư vú giai đoạn II - III tại bệnh viện ung bướu Hà Nội. Luận văn chuyên khoa cấp II, Trường Đại học Y Hà Nội; 2020.
9. Tạ Văn Tờ. Nghiên cứu hình thái học, hóa mô miễn dịch và giá trị của chúng trong ung thư biểu mô tuyến vú. Luận án tiến sỹ y học, Trường Đại học Y Hà Nội; 2004
10. Trần Văn Thuấn và cộng sự. Nghiên cứu ứng dụng các tiến bộ mới trong chẩn đoán và điều trị ung thư vú. Đề tài cấp nhà nước KC10-17/11-15; 2015.